Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
And talking of BS.....
Having done my due diligence, studied my charts and listened to the experts out there, I've bought back-in, largely through eventually ignoring all of those and resorting to one of my favourite investment measurements of choice..........that being my gut feeling whilst listening to the briefing earlier this week and noting how the smell of waffly BS appeared to have lifted.
This may drift a little in the coming weeks but that'll be down to the MM's taking advantage of a slight news void. Alternatively, they may think that we are basing our decisions around that thinking and stymy us by pushing it back up - imo!
Thinking back to a previous investment of mine involving liquid biopsies, I can remember somebody saying (probably the CEO) how the advantage of being able to take repeated liquid biopsies involved being able to check on how the chemo being used was affecting the tumor cells because the many types of chemo were often effectively a lottery for Oncologists. Others more knowledgeable on here (or those invested in that company) will be able to elaborate further. All of this does tie in with what CC said though and this understanding is pretty exciting imo.
Where the Coris and Launch Diagnostics acquisitions were concerned, weren't they most likely just down to AS's previous stated aims of several years ago when developing the LFT: for Avacta to become a household name on the wider testing front (beyond Covid). I just think his ego (yet again) got ahead of him and he didn't realise his limited capabilities on the finance front.
Sheppy, I wasn't surprised at all to see you jumping on the back of Rory's lengthy, perfectly fair and 'considered' post, largely because - looking at your last 20 posts, you have not offered one single substantive or constructive thought. Virtually every one of your posts boils down to one or two lines (max - feel free to check) of nothing other than sniping - an easy option for anyone who can do little more than think on an empty head. I am not a censor here as I am not actually invested at present but I have followed Avacta for several years. Personally, the only justification that I can see for your existence here is to ensure that full advantage of the filter box is taken.
Isn't the fact that it's just really tough to raise money at present, especially in this sector and market at present? Events at C4X and RedX Pharma are both worth reading about at present. The latter had done really well - both by way of some really big deals and cash in the bank but the market just wasn't giving them the credit they felt the deserved, hence they are getting out and looking elsewhere for funding. Feel free to correct me but that's how I saw it. AVCT were most likely advised accordingly?
"I'm young enough to wait"
Sooooo.......Timster.....ever seen a grown man naked?
(For those too young to remember the movie quote (Airplane - 1980)
https://youtu.be/wfgO90yGusI
Unless I've missed something and especially in view of some of the criticism he's received, good of AS to present at today's IMP meeting. My question to him - which could provide a fairly telling answer:
Looking at your actions as CEO over the past two years, what one thing would you have done differently in order to have improved your legacy?
The most worrying aspect of the Chairman's statement for me was the following para which has heightened my recent concerns. I have been very conscious of what has taken place at Redx and others - delisting from AIM and, more specifically, doing so off the back of the market failing to recognise their very strong positions (including having done some very big deals and with much cash in the bank); If more advanced companies such as those do not see the point of being on AIM then where does that leave Hemo on the future fund-raising front? Contrary and sensible arguments only by way of replies, please:
"While we accept that recent market conditions have been very difficult, we have been disappointed by the successively lower price at which we have had to carry out our fundraisings in the UK market, in the light of the progress we have made and the view taken by Prevail Partners concerning our status. The capital recently raised will undoubtedly take us materially further forward and we are now looking at a number of strategies for the future development of all three of our current product candidates."
Prof Sir Marc Feldmann AC, FRS
MB BS, PhD, FRCP, FRCPath, FAA, F Med Sci
Chairman
PL, I might be talking out of my backside here but looking at one of a number of recent stories concerning AIM biotechs - the following concerning C4X in particular - 'deals' don't appear to be enough in the current climate? Apologies in advance if I've misunderstood different circumstances at AVCT.
https://www.thebusinessdesk.com/northwest/news/2130947-c4x-to-quit-stock-market-and-seek-venture-funding-for-drug-discovery